-
公开(公告)号:KR101433049B1
公开(公告)日:2014-10-14
申请号:KR1020130085609
申请日:2013-07-19
Applicant: 충남대학교산학협력단
IPC: C12N5/10 , C12N15/12 , A01K67/027 , G01N33/15
Abstract: The present invention relates to a method for manufacturing an animal model in which Parkinson′s disease related to the expression of DJ-1 gene is induced, an animal model manufactured by the same, and a method for judging the effect of a treatment candidate substance or a medicine of Parkinson′s disease by using the animal model. According to the present invention, in a research of a research model for treating Parkinson′s disease and a medicine for treating Parkinson′s disease, not only is difference between a normal tissue and a Parkinson′s disease expressing tissue biochemically compared, but also substances applicable as a medicine for Parkinson′s disease is detected by using the animal model to quantitively compare and judge the effect.
Abstract translation: 本发明涉及一种制造其中诱导与DJ-1基因的表达相关的帕金森病的动物模型的制造方法,以及由该方法制造的动物模型以及用于判断治疗候选物质的作用的方法 或使用动物模型的帕金森病药物。 根据本发明,在用于治疗帕金森病的研究模型和治疗帕金森病的药物的研究中,不仅正常组织与表达组织的帕金森病之间的差异在生物化学上比较,而且 通过使用动物模型量化比较和判断效果,可以检测到适用于帕金森病药物的物质。
-
公开(公告)号:KR1020140107804A
公开(公告)日:2014-09-05
申请号:KR1020130021817
申请日:2013-02-28
Applicant: 충남대학교산학협력단
IPC: C12N15/65 , C12N15/62 , C12N5/10 , A01K67/027
Abstract: The present invention, as a method for mass-producing medicine to treat rheumatoid arthritis, relates to a method for producing medicine by expressing gene from mammary gland of a transformed animal using expression vector including base sequence specifically expressed and controlled in mammary gland of a pig. More specifically, the present invention is production of a pig, a transformed animal through somatic cell clone after making recombinant protein to mass-produce TNF-R fusion protein and then transfecting the recombinant protein into a somatic cell of a pig.
Abstract translation: 作为用于大规模生产药物治疗类风湿性关节炎的方法本发明涉及通过使用包括在猪的乳腺中特异表达和控制的碱基序列的表达载体来表达转化动物的乳腺基因来生产药物的方法 。 更具体地说,本发明是在制备重组蛋白质大规模生产TNF-R融合蛋白后,通过体细胞克隆生产转化动物,然后将重组蛋白转染到猪的体细胞中。
-
公开(公告)号:KR1020110022759A
公开(公告)日:2011-03-08
申请号:KR1020090080159
申请日:2009-08-28
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A cell therapeutic agent containing amniotic fluid-derived mesenchymal stem cells is provided to ensure superior differentiation ability. CONSTITUTION: A method for preparing canine amniotic fluid-derived mesenchymal stem cells comprises: a step of collecting amniotic fluid from a pregnant dog using a syringe; a step of centrifuging amniotic fluid to collect pellet; a step of culturing the pellet in a medium containing bFGF(basic fibroblast growth factor) and EGF(epidermal growth factor) and collecting cultured cells; and a step of isolating and purifying the stem cells. The method for further comprises a step of inducing cell adhesion. The medium contains 0.5-20 ng of bFGF, 1-40 ng of EGF, 1-40% FBS(fetal bovine serum), and 0.5-4% penicillin-streptomycin. A composition for controlling differentiation of mesenchymal stem cells to adipocytes contains FBS, IBMX, dexamethasone, indomethacin, and insulin as active ingredient.
Abstract translation: 目的:提供含有羊水间充质干细胞的细胞治疗剂,以确保优异的分化能力。 构成:用于制备犬羊水间充质干细胞的方法包括:使用注射器从怀孕犬采集羊水的步骤; 离心羊水收集颗粒的步骤; 在含有bFGF(碱性成纤维细胞生长因子)和EGF(表皮生长因子)的培养基中培养该颗粒并收集培养的细胞的步骤; 以及分离和纯化干细胞的步骤。 该方法还包括诱导细胞粘附的步骤。 培养基含有0.5-20ng的bFGF,1-40ng的EGF,1-40%的FBS(胎牛血清)和0.5-4%的青霉素 - 链霉素。 用于控制间充质干细胞分化为脂肪细胞的组合物含有FBS,IBMX,地塞米松,吲哚美辛和胰岛素作为活性成分。
-
公开(公告)号:KR101943158B1
公开(公告)日:2019-01-28
申请号:KR1020160117142
申请日:2016-09-12
Applicant: 충남대학교산학협력단
IPC: C12N15/873 , A01K67/027 , A61D19/04
-
公开(公告)号:KR102093146B1
公开(公告)日:2020-05-04
申请号:KR1020190045820
申请日:2019-04-19
Applicant: 주식회사 엠케이바이오텍 , 충남대학교산학협력단
IPC: C12M1/42
-
-
-
-